Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATX-101 with Chemotherapy in Recurrent Ovarian Cancer
NCT04814875Phase 2Terminated
- Start
- Sep 2021
- Primary completion
- Nov 2023
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ATX101 in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC). Started Sep 2021; status: terminated.
02
Drugs
ATX101
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT04814875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04814875.